| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary targets of PNU-96391A are dopamine D2 receptors (weak antagonist) and serotonin 5-HT2A receptors (partial agonist). As a monoaminergic stabilizer, PNU-96391A modulates dopaminergic and serotonergic neurotransmission in a state-dependent manner, normalizing both hyperdopaminergic and hypodopaminergic states. This mechanism is distinct from classical antipsychotics and may offer therapeutic advantages for motor and psychiatric symptoms in neurological disorders.
|
|---|---|
| ln Vitro |
In vitro, PNU-96391A acts as a weak dopamine D2 receptor antagonist and a partial agonist at 5-HT2A receptors. The compound demonstrates behavioral stabilizing properties in cellular assays. Its unique pharmacological profile as a monoaminergic stabilizer distinguishes it from classical antipsychotics and may contribute to its therapeutic effects in Huntington's and Parkinson's diseases. These in vitro activities establish PNU-96391A as a valuable tool for investigating monoaminergic stabilization.
|
| ln Vivo |
In vivo, PNU-96391A antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease. The compound demonstrates tolerability and efficacy in Huntington's disease in a double-blind cross-over study. Its monoaminergic stabilizing mechanism may offer therapeutic benefits for motor and psychiatric symptoms in these disorders. These in vivo activities support further investigation of PNU-96391A as a therapeutic agent for neurological disorders.
|
| Enzyme Assay |
The in vitro receptor binding assay for PNU-96391A involves the use of cell membranes expressing recombinant human dopamine D2 or serotonin 5-HT2A receptors. The assay is performed in 96-well plates containing assay buffer, a radiolabeled ligand such as [3H]-spiperone for D2 or [3H]-ketanserin for 5-HT2A, and increasing concentrations of PNU-96391A. Following incubation, the reaction is terminated by rapid filtration, and bound radioactivity is measured. Ki values are calculated from competition curves.
|
| Cell Assay |
The in vitro cell assay for PNU-96391A involves the culture of cells expressing dopamine D2 or serotonin 5-HT2A receptors, such as CHO or HEK293 cells. Cells are treated with PNU-96391A at various concentrations. Receptor activation is assessed by measuring downstream signaling such as cAMP inhibition (D2) or IP3 production (5-HT2A). Functional activity (antagonist vs. partial agonist) is confirmed by comparing responses with reference compounds.
|
| Animal Protocol |
The in vivo animal experiment for PNU-96391A involves the use of rodent models for assessing behavioral stabilization. Rats receive PNU-96391A via intraperitoneal or oral administration at various doses. Behavioral sensitization induced by dopamine agonists is assessed using locomotor activity monitoring. Motor function in Parkinson's disease models is assessed using rotational behavior or akinesia tests.
|
| References |
|
| Molecular Formula |
C15H24CLNO2S
|
|---|---|
| Molecular Weight |
317.872
|
| Exact Mass |
317.122
|
| CAS # |
156907-84-5
|
| Related CAS # |
(+)-OSU6162; 160777-43-5; (-)-OSU6162; 146798-66-5
|
| PubChem CID |
9836644
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
436.5ºC at 760 mmHg
|
| Flash Point |
217.8ºC
|
| Vapour Pressure |
8.04E-08mmHg at 25°C
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
374
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S(C)(C1=CC=CC(=C1)[C@@H]1CCCN(CCC)C1)(=O)=O
|
| InChi Key |
LEMGVHZVBREXAD-PFEQFJNWSA-N
|
| InChi Code |
InChI=1S/C15H23NO2S.ClH/c1-3-9-16-10-5-7-14(12-16)13-6-4-8-15(11-13)19(2,17)18;/h4,6,8,11,14H,3,5,7,9-10,12H2,1-2H3;1H/t14-;/m1./s1
|
| Chemical Name |
(3S)-3-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride
|
| Synonyms |
PNU-96391A; PNU 96391A; PNU96391A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1459 mL | 15.7297 mL | 31.4594 mL | |
| 5 mM | 0.6292 mL | 3.1459 mL | 6.2919 mL | |
| 10 mM | 0.3146 mL | 1.5730 mL | 3.1459 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
